ReachMD Faculty

Public Profile

Nicholas J. Silvestri, MD
Affiliations
Nicholas J. Silvestri, MD
    close

    Affiliations

    Associate Professor of Neurology Department of Neurology University at Buffalo Jacobs School of Medicine & Biomedical Sciences Buffalo, NY

    Program NameLast Air DateHosts/Guests
    Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
    • Vera Bril, MD
    • Nicholas J. Silvestri, MD
    Managing Side Effects in FcRn Therapy: Best Practices for gMG
    • Vera Bril, MD
    • Nicholas J. Silvestri, MD
    New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
    • Vera Bril, MD
    • Nicholas J. Silvestri, MD
    A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
    • Vera Bril, MD
    • Nicholas J. Silvestri, MD
    Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
    • Vera Bril, MD
    • Nicholas J. Silvestri, MD
    Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
    • Vera Bril, MD
    • Nicholas J. Silvestri, MD
    Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies03/30/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions03/21/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy03/31/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action03/22/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Balancing Risk and Benefit: Traditional MG Treatments and Medications to Avoid02/25/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Autoantibodies in MG: Their Role in Diagnosis and Treatment03/18/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Diagnosing gMG: Navigating Current Tools and Approaches03/25/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Life-Threatening Events: Understanding and Preventing Myasthenic Crisis03/23/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Understanding Disease Progression: The Shift From Ocular to Generalized MG03/25/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Beyond the Symptoms: The True Impact of gMG on Patients' Lives03/31/2025
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    FcRn Inhibitors: A Potential New Targeted Therapy Option
    • Nicholas J. Silvestri, MD
    Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes03/29/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Clinical Benefits of FcRn Inhibitors Clinical Benefits: Innovations in CIDP Management and Treatment03/17/2025
    • Nicholas J. Silvestri, MD
    • Jeffrey Allen, MD
    Novel Mechanisms of Action: FcRn Inhibitors03/23/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Implementing CIDP Clinical Guidelines: Optimizing Therapy03/30/2025
    • Nicholas J. Silvestri, MD
    • Jeffrey Allen, MD
    CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment03/23/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations03/28/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Autoantibodies in CIDP: Prevalence and Diagnostic Implications03/27/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP03/15/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools03/22/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Decoding CIDP: Exploring Common and Atypical Variants03/27/2025
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD
    Improving Outcomes Earlier in Generalized Myasthenia Gravis:  Roadmap for Incorporating Targeted Th…
    • Nicholas J. Silvestri, MD
    • James F. Howard, Jr, MD
    Incorporating FcRn Inhibitors Into Clinical Practice in Chronic Inflammatory Demyelinating Polyneur…
    • Jeffrey Allen, MD
    • Nicholas J. Silvestri, MD

    Program Chapters

    Segment Chapters

    Playlist:

    Recommended

    Register

    We’re glad to see you’re enjoying ReachMD…
    but how about a more personalized experience?

    Register for free
    PrevNext